
It's Never Too Late For Your First Facial
As Rivas is relaying this, she has started work. 'First step, proper cleansing,' she says. This involves swirling an oil cleanser over my face in smooth, rhythmic waves. Cleaning is for Rivas numero uno. 'People will do it in the morning, but not at night, or the other way around; it's important to educate people on the importance of proper cleansing.' Then Rivas begins an oxygen treatment. 'You wouldn't know this [she has assumed correctly] but oxygen has been used a lot in facials over the years,' she says. If those involve an external infusion of oxygen to the skin, Rivas wants to create an oxygen-starved surface to the skin, to encourage the body to oxygenate from within. This involves applying a gently abrasive pad that she glides over my skin, likely causing it to feel, in her words, spicy. In fact, it actually feels great; a little heat building as the lightly whirring pad is moved across my face, but none of the slightly burning feeling my skin can get if it goes near any heat source.
Now we are onto the extraction moment. I brace myself for the pinching. But—get this—Rivas says, 'You have what everyone wants. You have very small pores, which is great. And when you have small pores like these, it's harder to do extractions. I don't recommend doing this at home yourself.' (Noted: No more peering into the bathroom mirror.)
Lastly, she finishes with a massage, working both face and neck. It feels incredible, but also, for someone who has had a sum total of two massages in his life, a reminder that you can find yourself connecting with your body—and now, I guess, face—differently because the muscles are being stimulated in ways you're not used to. A spot of sunscreen (okay, I am converting!) and with that we're done. She leaves me to put my sweater back on, but first I have to stare into the mirror. I can never take a compliment about myself, so I will compliment Rivas instead: She has made my skin look a-mazing; brighter, lighter, softer, but maybe just as importantly, it feels great.
I walk to the subway to go home, and almost don't want to take it, to not come into contact with the grime of the city after what has felt like an experience that was both utterly ethereal yet also so physical. I wasn't prepared for my skin to be so improved, and nor was I prepared for the realization that my avoidance of getting a facial was a strange avoidance of judgement on how well, or not, I look after my skin, and in a way, an extension of how well I look after myself. Rivas is a terrific facialist, for sure, but what makes her so good is her ability to sensitively intuit how to work with her clients.
As I left, she had thoughts. 'Let's work on the pigment, let's work on building more collagen, more elastin in your skin,' she told me, 'so maybe some microchanneling and maybe some retinol at home—that kind of thing. I don't need you worrying about blackheads. And if you really have to focus, my focus for you would be sunscreen.' All sound (and do-able) advice, but perhaps more importantly, Rivas has turned looking into the mirror every morning, noon, and night as an act of looking ahead, not just looking at the right now.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Sage, following Setbacks, to sell to Supernus for $561M
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Sage Therapeutics, a brain drug developer that's dealt with a series of clinical setbacks, has agreed to be acquired by Supernus Pharmaceuticals in a deal worth $561 million. Supernus on Monday said it would pay $8.50 per share for Sage, an offer valuing shares at a roughly 27% premium to their previous closing price. The deal also includes a contingent value right worth up to $3.50 per share if certain sales and commercial milestones related Sage's lone product, the postpartum depression drug Zurzuvae, are met. Sage earlier this year turned down a $7.22-per-share offer from Zurzuvae development partner Biogen and sued the company, arguing it was being undervalued. The company has been evaluating 'strategic alternatives,' a process that included a search for a buyer, ever since. Sage has gone through a roller coaster ride since its founding more than a decade ago. Launched by Third Rock Ventures and run for many years by biotech veteran Jeff Jonas, the company aimed to develop brain drugs for a variety of conditions, from epilepsy and tremors to Huntington's disease. The company went public in 2014 to support that work and saw its share price swell to nearly $200 apiece a few years later as a pair of depression medicines advanced through testing. It brought to market not only the first medicine for postpartum depression, Zulresso, but the first pill for the condition, called Zurzuvae. It cut a multibillion-dollar partnership deal with Biogen, too. But Zulresso, a 60-hour infusion, never generated significant sales and Sage stopped marketing it at the end of the year. And the company had initially hoped to bring Zurzuvae to market for major depressive disorder — a much larger opportunity — but changed course and laid off staff after U.S. regulators asked for additional testing. Sage has suffered setbacks elsewhere, too, with experimental drugs failing studies in epilepsy, tremors, Alzheimer's, Huntington's and Parkinson's disease over the years. Company shares closed on Friday at $6.70 apiece and have fallen so low in recent months that Sage's board accused Biogen of lowballing the company with an earlier bid. The deal with Supernus feels 'like an unremarkable outcome for a company that was once one of the hottest stories' in brain drug research, wrote Stifel analyst Paul Matteis in a note to clients Monday. Matteis added that, for investors, though, the acquisition 'is a good end to the Sage story given the host of challenges facing the company.' In a separate note, RBC Capital Markets' Brian Abrahams called Supernus' offer 'fair' given the 'considerable time' it would have taken for Sage to become profitable. Abrahams also wrote that there is a 'very low likelihood' that Sage hits the majority of the sales targets that would bump up its sale price. Sage stockholders would get $1 per share if Zurzuvae hits $250 million in sales in the U.S. by 2027, and similar payouts if U.S. drug sales reach $300 million by 2028 and $375 million by 2030. Zurzuvae generated $72 million in U.S. sales in 2024. Biogen and Sage split U.S. profits. Recommended Reading Moderna inks another gene editing deal Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


CBS News
28 minutes ago
- CBS News
Growing number of Americans 55 and older are experiencing homelessness. Health workers worry about the "most vulnerable."
Why is the homeless population getting so much older? Homelessness in America has been steadily ticking up in recent years. In 2024, the United States saw an 18% increase in the homeless population from the year before — and those providing essential services like health care and housing assistance say they're most concerned about the aging population. More than 140,000 Americans who are 55 or older are experiencing homelessness on any given day, and that number is estimated to nearly triple by 2030, according to a 2019 report. Rose Del Rosario is among the aging homeless population growing across the United States. The 65-year-old has high blood pressure and lifelong asthma. One morning, she received an atypical house call from Daniel Speller, a physician associate with Healthcare in Action, a nonprofit providing assistance to people like Del Rosario across California. Speller took her vitals inside a medical van parked across the street from her RV in San Pedro. Del Rosario doesn't have health insurance, so she would sometimes purchase inhalers from people or find them in the trash. While she said she doesn't feel safe using them, she had no money left after her husband died several years ago — and that's how she wound up on the streets. When asked how she feels about navigating homelessness at this age, she said it makes her feel older. "I feel like it's aging me. I feel like it's aging me a lot," Del Rosario told CBS News. "It's just hard to live like this." Rose Del Rosario, 65, of California is among the growing population of seniors across the U.S. who are experiencing homelessness. CBS News Approximately 20% of the more than 771,000 people who were unhoused in the U.S. as of January 2024 were 55 and older, according to the Department of Housing and Urban Development's data. Homelessness is often caused by the death of a spouse, divorce, joblessness, eviction or mounting medical issues, the U.S. Interagency Council on Homelessness says. "These are folks entering the stage where they're starting to have multiple complex chronic medical conditions that need to be met, and they're just not being met," Speller told CBS News. "They're also the most vulnerable." Dennis Culhane, a professor at the University of Pennsylvania whose research focuses on homelessness and assisted housing policy, told CBS News that the aging trend in the homeless population has been going on for 30 years. The second half of the Baby Boomers generation — those born between 1955 and 1964 — have constituted the largest subsegment of the U.S. population since 1990, Culhane explained on "CBS Evening News." Because there are more of them, it puts them at higher risk of homelessness, Culhane said, but there are also other factors. "They came of age in the early 1980s at a time when there was very high unemployment and housing costs were rising," he said. "A lot of these folks were unable to get into the labor market by their mid-20s, so they've struggled for years trying to get a toehold in the workforce." When asked about the impact of the trend of public policy, Culhane said the major impact is on health care systems. "They end up hospitalized at very high rates. They often can't be discharged in a timely fashion because they have no place to go back to and no family to support them. So they often will end up in nursing homes, even though in those nursing homes they will often get discharged right back into homelessness," Culhane said. Healthcare in Action CEO Dr. Indu Subaiya said she fears the impact rising costs and potential cuts to government programs like Medicaid will have on seniors. "I don't believe we should be cutting Medicaid for those populations. We should leave those intact. And that will be so, so helpful to people not falling further into the hole," Subaiya told CBS News. At 65 years old, Del Rosario says she thought she'd be somewhere else for retirement. "On a nice comfortable rocking chair waiting for the casserole to come out of the oven," she said. "I didn't think it would be like this."
Yahoo
34 minutes ago
- Yahoo
Why Novo Nordisk Stock Sank by Nearly 4% Today
A monster rival will soon begin offering its highest-dose weight loss drugs through its website. On top of that, an analyst cut his price target on the Denmark-based pharmaceutical company. 10 stocks we like better than Novo Nordisk › Novo Nordisk (NYSE: NVO) stock had a Monday to forget, as news from a top rival dampened sentiment on the Danish pharmaceutical company. A price target cut from an analyst tracking the company only exacerbated the situation. By market close that day, Novo Nordisk's shares were down by 3.5%, in contrast to the generally buoyant S&P 500 (SNPINDEX: ^GSPC), which edged almost 1% higher. That rival is none other than giant U.S. pharmaceutical company Eli Lilly. It announced that it will make the highest dosages of its Zepbound weight-loss drug available to any adult with a qualifying prescription via its website beginning in August. Zepbound, a direct competitor to Novo Nordisk's pioneering Wegovy, is already available on Lilly's website, albeit in lower doses. With the addition of the two highest-dose versions, all dosages of the drug will be offered through the company's portal. With this, Eli Lilly has a fine chance of poaching more market share from the European company. Meanwhile, well before the market open, J.P. Morgan prognosticator Richard Vosser cut his price target on the company. He now feels its Denmark-listed stock is worth 650 kroner ($101) these days, down significantly from his previous fair-value assessment of 1,000 kroner ($155). He maintained his overweight (i.e., buy) recommendation, however. Neither of these developments is positive for Novo Nordisk. However, investors didn't react by panic-selling the stock; instead, it suffered only a minor sell-off. This is telling; Wegovy is still a hotly popular drug and should remain so, given the high levels of obesity in this country, and Americans' desire for a relatively easy fix for this. Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,702!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $870,207!* Now, it's worth noting Stock Advisor's total average return is 988% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Why Novo Nordisk Stock Sank by Nearly 4% Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data